Ao longo do processo de progressão tumoral, se observa alteração na expressão de glicoconjugados contendo oligossacarídeos N-ligados. Uma das formas mais comuns de glicosilação aberrante observada em células transformadas e em tumores humanos é representada por (poli)lactosaminas presentes em oligossacarídeos N-ligados. Estes glicanos são ligantes de galectina-3. Com o objetivo de identificar a expressão e distribuição dos ligantes de galectina-3 associados a processos fisiopatológicos, como a transformação maligna, desenvolvemos uma proteína quimérica, a galectina-3 conjugada a fosfatase alcalina (Gal-3/FA). Observamos que a Gal-3/FA possui a mesma especificidade de galectina-3 e que pode ser usada como sonda em ensaios de overlay e ensaios de imunoistoquímica. Entre os ligantes de galectina-3 identificamos a ?1 integrina, mediador de processos biológicos dependentes da interação célula-matriz como a migração celular. Linhagens de células de origem mesenquimal derivadas de tumores induzidos com metilcolantreno de animais selvagens (linhagens S11 e S12) e nulizigoto (linhagem ?12) para o gene da galectina-3 foram estabelecidas. Avaliamos a capacidade migratória dessas células e os nossos resultados mostraram que células que expressam galectina-3 são mais migratórias em superfícies de laminina-1. Este dado sugere que a galectina-3 seja um modulador positivo do processo de migração celular em superfícies de laminina-1. No entanto, o mecanismo pelo qual a galectina-3 medeia esse processo não é conhecido. Células que possuem fenótipo mais migratório apresentam um estado intermediário de adesão. Nós observamos que a galectina-3 se encontra nos complexos focais. Na presença de galectina-3 observamos diminuição de FAK fosforilado e recrutamento da fosfatase SHP-2 para os complexos focais. A diminuição de FAK fosforilado no lamelipódio leva ao turnover dos complexos focais e ao aumento da migração celular. Analisamos também a via de sinalização e observamos que a galectina-3 não ativa PAK. Contudo, o inibidor de PI3quinase, wortmanina, inibiu o efeito pró-migratório de galectina-3. Esses dados reforçam a noção do papel de galectina-3 na modulação do processo de migração de fibroblastos transformados, funcionando como uma molécula / Altered expression of cell surface N-linked oligosaccharides are often associated with malignant transformation of cells. One of the most common forms of aberrant glycosylation in transformed cells and human tumors is the highly elevated ?1,6 branching of N-linked oligosaccharides caused by increased expression of N-acetylglucosaminytransferase V (Mgat5). Galectin-3, a ?-galactoside binding protein, binds preferentially to poly-N-acetyllactosamines, which are the products of Mgat5. In order to exploit this hallmark of cancer cells, we have developed a tool for in situ identification of these tumors associated glycoconjugates. Human galectin-3 was fused to bacterial alkaline phosphatase, generating a hybrid molecule displaying both the carbohydrate binding properties of galectin-3 and enzymatic activity of alkaline phosphatase (Gal-3/FA). Gal-3/FA has the same fine of galectin-3 which was confirmed in direct binding assays. The tool presented herein was therefore useful for several immunoenzymatic assays, and will allow to establish whether the expression pattern of galectin-3 ligands have any physiological or clinical significance. We have identified ?1 integrin as a galectin-3 ligand. ?1 integrins are the actual effector of cell adhesion and migration. We have established cell lines from methylcholantrene-induced sarcomas from both wild type and galectin-3 null mice. In this system, galectin-3 null cells were less migratory than control cells in laminin-1. When galectin-3 was transiently expressed in galectin-3 null sarcoma cells, it inhibited cell adhesion to laminin-1 and stimulate the migratory response to laminin-1. The addition of exogenous galectin-3 also enhanced the migratory capacity of ?12 cells in a carbohydrate dependent way. Galectin-3 was found in focal contacts of ?12 cells where it may interact with many glycoproteins containing polyllactosamines on the cell surface. Here we showed that ?1 integrins are among them. Exogenously added galectin-3 led to a decrease in phosphorylated-FAK in lamellipodia and increased the recruitment of Shp-2 phosphatase of migrating cells. The effect of galectin-3 in migration was not dependent on the activation of the p21-activated kinase (PAK). Wortmannin inhibited the increased migration elicited by galectin-3, suggesting the involvement of the PI3-kinase signaling in the galectin-3 pathway. We propose that extracellular galectin-3 bound ?1integrins and disrupted the focal adhesion plaque, thus favoring cell migration.

La galectine-9 est une lectine animale principalement exprimée dans un contexte inflammatoire et possédant des propriétés à la fois pro-inflammatoires et immunosuppressives. Elle induit la production de cytokines inflammatoires par les cellules du système immunitaire inné tandis qu’elle induit l’apoptose des lymphocytes Th1 CD4+ et favorise l’expansion des lymphocytes Treg. Les propriétés immunomodulatrices de la galectine-9 dépendent en grande partie de son interaction avec le récepteur TIM-3. Cependant, ces deux molécules interagissent chacune avec d’autres protéines et dans plusieurs contextes la responsabilité de l’interaction galectine-9/TIM-3 n’a pas été formellement démontrée. Le développement d’un anticorps neutralisant les effets de la galectine-9 permettrait de préciser son rôle exact dans ces contextes. Par ailleurs, le blocage des voies de signalisations inhibitrices du système immunitaire est aujourd’hui un enjeu majeur en oncologie, comme le démontre le succès récent de la neutralisation du récepteur inhibiteur CTLA-4 pour le traitement des mélanomes. Nous avons produit de nouveaux anticorps monoclonaux dirigés contre la galectine 9 par immunisation de souris avec la partie C-terminale de la protéine. Parmi ces anticorps, 1G3 permet la détection de la galectine-9 sur coupes de tissus humains d’une manière très sensible et spécifique en immunohistochimie. Son utilisation nous a permis de confirmer l’expression constante et intense de la galectine-9 dans les cellules malignes de carcinome nasopharyngé et la forte expression de la galectine-9 dans les cellules de Kupffer présentes dans les tissus hépatiques infectés par le virus de l’hépatite C. Pour la première fois, nous avons mis en évidence une expression de la galectine-9 dans les leukocytes infiltrant les tissus hépatiques infectés par le virus de l’hépatite B. De plus, nous observons une expression de la galectine-9 dans les hépatocytes infectés par ces deux virus, ce qui n’avait pas été démontré jusqu’à présent. Nous avons également caractérisé les capacités fonctionnelles de nos anticorps lors de tests in vitro. L’anticorps 2E12 bloque la fixation de la galectine-9 au récepteur TIM-3 dans un test acellulaire, neutralise l’apoptose induite par la galectine-9 sur cellules de lymphomes T humaines et réduit considérablement l’augmentation de calcium cytosolique induite par la galectine-9 dans les cellules Jurkat. Ces effets de la galectine-9 sont indépendants de TIM-3 dans ce modèle cellulaire. L’anticorps 2E12 constitue un outil puissant pour étudier les fonctions de la galectine-9 à la fois dépendantes et indépendantes de TIM-3. / Galectin-9 is an animal lectin mainly expressed in an inflammatory context which possesses both pro-inflammatory and immunosuppressive properties. It induces inflammatory cytokines production from innate immunity cells whereas it induces apoptosis of Th1 CD4+ lymphocytes and enhance T regulatory lymphocytes expansion. Galectin-9 immunomodulatory properties depends mostly on its interaction with TIM-3 receptor. However, both molecules interact with other proteins, and in several contexts, galectin-9/TIM-3 interaction responsability has not been formally demonstrated. Development of a galectin-9 neutralizing antibody would allow to determine its precise role in those contexts. Moreover, blocking of immune system inhibition pathways is nowaday a major concern in oncology, as the success of CTLA-4 antagonist used for melanoma treatment recently demonstrated. We have produced new monoclonal antibodies against galectin-9 through immunisation of mice with the C-terminus part of the protein. Among those antibodies, 1G3 allows the detection of galectin-9 on human tissue samples in a very sensitive and specific manner in immunohistochemistry. Using 1G3, we could confirm intense and constant expression of galectin-9 in nasopharyngeal carcinoma malignant cells and its strong expression in Kupffer cells infiltrating hepatitis C-infected liver tissue. For the first time, we demonstrated expression of galectin-9 in leukocytes infiltrating hepatitis B-infected liver tissue. Additionally, we could observe galectin-9 expression in infected hepatocytes for both viruses, which had not been demonstrated until now.We also characterized functional properties of our antibodies during in vitro tests. The 2E12 antibody blocks galectin-9 interaction with TIM-3 in an cell-free assay, neutralizes galectin-9-induced apoptosis of human T lymphomas cells and considerably reduces galectin-9-induced increase of intracellular calcium in Jurkat cells. Those effects are independent of TIM-3 in this cell line model. The 2E12 antibody constitutes a powerful too to study both TIM-3-dependent and TIM-3-independent functions of galectin-9.

A galectina-1 (Gal-1) é uma lectina que reconhece ?-galactosídeos e participa de vários processos biológicos, incluindo a modulação da resposta inflamatória. Dados da literatura mostram a participação desta lectina na indução da exposição de fosfatidilserina (FS - um marcador de apoptose), na geração de espécies reativas do oxigênio (EROs) e na modulação quimiotática de neutrófilos. Entretanto, ainda são escassos os dados relacionados ao impacto biológico da Gal-1, exógena e endógena, sobre a biologia destas células. Neste trabalho foram avaliados, in vitro, alguns aspectos funcionais da interação Gal-1/neutrófilo. Determinou-se o nível de expressão da Gal-1 (Western Blotting) e de seu mRNA (PCR real time), em leucócitos humanos obtidos do sangue periférico de doadores sadios e em células da linhagem promielocítica humana (HL-60). Leucócitos do sangue periférico e células HL-60 não expressam níveis detectáveis da proteína e também do mRNA para Gal-1. Por meio de ensaios de quimiluminescência (QL) foi possível analisar a capacidade da Gal-1 recombinante humana de induzir e modular a produção de EROs em neutrófilos humanos não ativados e ativados com fMLP (n-Formil-Methionyl-Leucyl-Phenylalanine). A Gal-1 induz a produção de EROs de modo dose-dependente em neutrófilos ativados com fMLP. Entretanto, em neutrófilos não ativados esta lectina não induz o metabolismo oxidativo e, além disso, é capaz de modular negativamente a produção de EROs em resposta ao fMLP. Tanto nas células não ativadas quanto ativadas com fMLP, os efeitos da Gal-1 na produção de EROs estão parcialmente associados a sua propriedade lectínica. Na literatura ainda não há relatos sobre a interferência da Gal-1 no metabolismo oxidativo em neutrófilos ativados com repetidas doses de fMLP. Sabe-se que o tratamento sucessivo com fMLP reduz os níveis de produção de EROs por neutrófilos, no entanto, a presença de Gal-1 não interferiu neste processo. Interessantemente, neutrófilos recuperados do peritônio de camundongos Gal-1-/- liberam mais EROs em resposta ao fMLP e a Gal-1 exógena quando comparado aos neutrófilos de animais selvagens. Com base nos achados in vitro e sabendo que na sepse polimicrobiana o neutrófilo desempenha um papel importante, o próximo passo foi utilizar o modelo de M-CLP (sepse moderada) em camundongos destituídos (Gal-1-/-) ou não (Gal-1+/+) do gene da Gal-1. Animais Gal-1-/-, apresentam menor taxa de sobrevivência. O influxo de neutrófilos e a carga bacteriana no peritônio são maiores nos animais Gal-1-/- apesar da menor quantidade de bactérias detectadas no sangue, em relação aos animais selvagens. No pulmão, o influxo de neutrófilos é semelhante para ambos os grupos. No entanto, após a injeção intraperitoneal de 107 Unidades Formadoras de Colônias (UFC) de bactérias, camundongos Gal-1-/- apresentam maior atividade bactericida no lavado peritoneal e sangue, em relação aos selvagens. A participação da Gal-1 na homeostase de neutrófilos foi demonstrada in vitro, por citometria de fluxo (anexina-V-FITC), onde a indução de FS nos neutrófilos tratados com Gal-1 favoreceu a fagocitose destas células por macrófagos. Portanto, este conjunto de resultados sugere que a Gal-1, exógena ou endógena, pode modular funções imunológicas de neutrófilos e participar da regulação do processo inflamatório/infeccioso sistêmico. / Galectin-1 (Gal-1) is a lectin that recognizes ?-galactosides and participates in biological processes, including modulation of the inflammatory response. Literature data show the involvement of this lectin to induce exposure of phosphatidylserine (PS - a marker of apoptosis), in the generation of reactive oxygen species (ROS) and in modulation of neutrophil chemotaxis. However, there are few data related to the biological impact of exogenous and endogenous Gal-1 on the biology of these cells. This study evaluated, in vitro, some functional aspects of the interaction of Gal-1 and neutrophil. It was determined the expression level of Gal-1 (Western blotting) and its mRNA (real time PCR) on human leukocytes obtained from peripheral blood of healthy donors and human promyelocytic cell line (HL-60). Peripheral blood leukocytes and HL-60 cells do not express detectable levels of this protein as well as the Gal-1 mRNA. Through chemiluminescence testing (CL) it was possible to analyze the ability of recombinant human Gal-1 to induce and modulate the production of ROS in naïve and activated (n-Formyl-Methionyl-Leucyl-Phenylalanine-fMLP) human neutrophils. Gal-1 induces ROS production in a dose-dependent way in fMLP activated neutrophils. However, in naive neutrophils this lectin does not induce oxidative stress and can negatively modulate ROS production in response to fMLP. The effects of Gal-1 on ROS production in both non-activated cells and activated cells are partially associated with their lectin property. In the literature there are no data about the interference of Gal-1 on ROS production in activated neutrophils with repeated doses of fMLP. It is known that the subsequent treatment with fMLP reduced levels of ROS production by neutrophils; however, the presence of Gal-1 did not affect this process. Interestingly, peritoneum neutrophils from Gal-1-/- mice release more ROS in response to fMLP and exogenous Gal-1 when compared to neutrophils from wild type animals. Based on the in vitro findings and considering that in polymicrobial sepsis, neutrophils play an important role, the next step was to use the M-CLP model (moderate sepsis) in mice lacking (Gal-1-/-) or not (Gal-1+/+) Gal-1 gene. Gal-1-/- animals present lower survival rate and fewer bacteria in the blood despite having higher bacterial load in infectious focus in relation to wild type mice. The rates of neutrophils influx into the peritoneum and lungs are similar for both groups. The participation of Gal-1 in the homeostasis of neutrophils was demonstrated in vitro by flow cytometry (annexin V-FITC), where induced PS by Gal-1 in the neutrophils enhanced the phagocytosis of these cells by macrophages. Therefore, this set of results suggests that Gal-1, exogenous or endogenous, can modulate immune functions of neutrophils and participate in the regulation of inflammatory/infectious disorders.

Helicobacter pylori are unique in their ability to colonise the human gastric mucosa. They persist lifelong in untreated individuals despite the presence of a continuous and specific immune response being mounted against it. H. pylori O-antigen is thought to be involved in immune-evasion and subversion by the bacteria and expression has been shown to facilitate colonisation and exacerbate pathology in murine models. This study investigates immuno-relevant roles of H. pylori O-antigen as a pathogen-associated molecular pattern (PAMP) and its interaction with two pattern recognition receptors (PRRs); galectin-3 and DC-SIGN. These PRRs possess distinct carbohydrate recognition domain (CRD) structures and binding affinities. Despite this, we have demonstrated that they compete for adhesion to both Lewis antigen glycoconjugates and whole cell H. pylori 26695 in solid phase binding assays. Galectin-3 significantly reduces DC-SIGN adhesion at a 2:1 stoichiometric ratio in both Lex glycoconjugate and whole cell H. pylori 26695 assays, and abrogates carbohydrate-specific binding in Lex glycoconjugate assays at a 22:1 ratio. These results suggest that galectin-3 may play a role in inhibiting or modulating the interaction between H. pylori O-antigen and DC-SIGN in vivo. Supporting this, we have shown that galectin-3 secreted by AGS cells during competitive infection with H. pylori 26695 is sequestered by H. pylori O-antigen. We have demonstrated that competitive infection of the O-antigen deficient mutant H. pylori 26695 galE in DC-SIGN expressing THP-1 cells reveals a significant reduction in intracellular survival at 8 hours compared to H. pylori 26695 Wt. Co-incubation of H. pylori 26695 Wt with 10 µg ml-1 galectin-3 reduced intracellular survival to the levels of H. pylori 26695 galE at 8 hours. Furthermore, H. pylori 26695 galE displayed rapid association of the endocytic markers Rab5 and Rab7 at 15 minutes compared to H. pylori 26695 Wt. Monoclonal antibody-mediated blocking of DC-SIGN in H. pylori 26695 Wt-THP-1 infections resulted in rapid association of the endocytic markers Rab5 and Rab7, corresponding to that of H. pylori 26695 galE, indicating that DC-SIGN-O-antigen interactions alters intracellular processing of the bacteria and reduces the rate at which these markers are recruited. Together these results elucidate novel mechanisms of H. pylori O-antigen and its interaction with galectin-3 and DC-SIGN that warrant further investigation in vivo. The identification of two PRRs competing for the same PAMP is unconventional and inspires a re-evaluation of PRRs in innate immune recognition.

Os melanomas correspondem a 7% de todas as neoplasias malignas em cães e são principalmente encontrados em cavidade oral e lábios, correspondendo a 33% dos tumores de boca, possuem um prognóstico ruim devido ao fato de serem diagnosticados tardiamente, por sua grande capacidade de invasão local e formação de metástases, além de altas taxas de recidiva após o tratamento cirúrgico. A Galectina-3 (Gal-3) é uma proteína responsável por diversas funções fisiológicas como adesão, apoptose, angiogênese, proliferação e diferenciação. Em medicina veterinária existem poucos estudos relacionando à expressão da Gal-3 com prognóstico e a progressão da neoplasia. Realizamos imuno-histoquímica para Gal-3 em 27 melanomas orais caninos que foram avaliados de maneira semiquantitativa e quantitativa, e comparamos os resultados obtidos com a sobrevida, outros marcadores prognósticos (Ki67, índice mitótico e atipia nuclear), expressão de proteínas relacionadas à apoptose (BCL2 e CASP3) e parâmetros histopatológicos (grau de pigmentação e tipo histológico). Detectamos alta expressão de Gal-3 em melanomas com maior sobrevida pós-cirúrgica e uma alta expressão nuclear de Gal-3 em melanomas com menor sobrevida pós-cirúrgica. Além disso, houve correlação entre as expressões de Gal-3 e BCL2, assim como entre atipia nuclear e sobrevida pós-cirúrgica. É sabido que a Gal-3 é capaz de formar heterodímeros com a BCL2 no citoplasma para atuar na evasão da morte por apoptose, impedindo a liberação da citocromo C. Já no núcleo, a Gal-3 induz à parada do ciclo celular, reduzindo a taxa da proliferação. Apesar do reduzido número amostral devido à dificuldade nos acompanhamentos clínicos nossos dados permitem sugerir que a Gal-3 é possui potencial para ser um marcador prognóstico de sobrevida em casos de melanomas orais caninos. Novos estudos devem ser realizados afim de confirmar nossas observações e elucidar o papel da Gal-3 nesta neoplasia. / Melanomas are almost 7% of all malignant neoplasms in dogs. They are mainly found in the oral cavity and lips, corresponding to 33% of tumors of the oral cavity. They carry a poor prognosis because of late diagnoses, local invasiveness, high metastatic and recurrence rates after surgical treatment. Galectin-3 (Gal-3) is a protein with a variety of biological roles such as in adhesion, apoptosis, angiogenesis, proliferation and differentiation. In veterinary medicine, there are few studies comparing the expression of Gal-3 with prognosis and tumor progression. We performed immunohistochemistry for Gal-3 in 27 canine oral melanomas and evaluated the immunolabelling both semi-quantitatively and quantitatively. The results were compared with survival, other prognostic markers (Ki67, mitotic index and nuclear atypia), expression of proteins related to apoptosis (BCL2 and CASP3) and histopathological parameters (degree of pigmentation and histological type). We detected higher expression of Gal-3 in cases of melanoma that presented longer post-surgical survival and a higher nuclear expression of Gal-3 in dogs with melanoma that had shorter post-surgical survival. In addition, there was correlation between the Gal-3 and BCL2 expressions, as well as between nuclear atypia and post-surgical survival. It is known that Gal-3 is able to form heterodimers with BCL2 in the cytoplasm leading to evasion of apoptosis, through preventing mitochondrial cytochrome C release. Nuclear Gal-3 induces the cell cycle arrest, reducing the proliferation rate. Despite the small sample size due to the difficulty in clinical follow-up, our data suggest that Gal-3 has the potential to be a prognostic marker for survival in cases of canine oral melanomas. Further studies should be performed to confirm our observations and elucidate the role of Gal-3 in this neoplasm.

A galectina-1 (Gal-1) é uma proteína que reconhece -galactosídeos e participa de vários processos biológicos, incluindo a modulação da resposta imunológica. Vários relatos da literatura reportam o potencial uso terapêutico da Gal-1 para doenças auto-imunes, inflamatórias, degenerativas e infecciosas. Entretanto, são escassos os relatos sobre o envolvimento da Gal-1 na doença causada por Tripanosoma cruzi. O presente trabalho tem como objetivos o estudo da participação da Gal-1 endógena e exógena na evolução da infecção aguda experimental por T. cruzi. Galectina-1 recombinante, camundongos C57BL/6 deficientes (nocaute - Gal-1-/-) ou não (selvagem - Gal-1+/+) do gene da galectina-1 e macrófagos desses animais foram utilizados em experimentos de infecção in vivo e/ou in vitro. Os animais foram infectados com tripomastigotas de T. cruzi da cepa Y, por via intraperitoneal. Os parâmetros analisados na caracterização do processo de infecção foram: parasitemia e sobrevivência; histopatologia do tecido cardíaco; dosagem de óxido nítrico, pelo método de Griess; imunofenotipagem de leucócitos, por citometria de fluxo; dosagem de citocinas por ELISA e taxa de liberação de parasitas em cultura de macrófagos. Os camundongos Gal-1-/- ou Gal-1+/+ tratados com Gal-1 exógena apresentaram as menores taxas de parasitemia. De modo interessante, todos os camundongos Gal-1-/- sobreviveram à infecção, enquanto que os selvagens apresentaram uma drástica redução de sobrevivência após o desafio com T. cruzi. A ausência da Gal-1 endógena ou o tratamento com a Gal-1 exógena provocou no músculo cardíaco de camundongos infectados uma significativa redução infiltrado inflamatório. As dosagens de citocinas séricas indicaram que animais selvagens infectados e tratados com Gal-1 apresentaram uma diminuição de IFN- em relação aos não tratados. Além disso, soros de animais nocautes infectados apresentaram níveis inferiores de diferentes citocinas (TNF-, IFN- , IL-4, IL-10 e IL-12) em comparação com amostras séricas de animais selvagens infectados. As porcentagens de diferentes tipos de células esplênicas (T, B, macrófagos, NKT e NK) foram, geralmente, maiores em camundongos selvagens do que em nocautes após a infecção por T. cruzi. Curiosamente, na cavidade peritoneal de camundongos Gal-1-/- ocorreu um aumento de neutrófilos e macrófagos após 12h ou 24h da infecção, respectivamente. O pico de produção de NO induzido por T. cruzi em macrófagos Gal-1-/- foi mais precoce e intenso do que o obtido por macrófagos Gal-1+/+. Além disso, os macrófagos Gal-1-/- liberaram menos parasitas in vitro em comparação como os macrófagos Gal-1+/+. Com base nesse conjunto de resultados sugerimos que a ausência de Gal-1 endógena ou o tratamento de animais com Gal-1 exógena promoveram perfis imunológicos (resposta inata e adaptativa) favorecedores da resolução da infecção experimental aguda por T. cruzi. / Galectin-1 (Gal-1) is a -galactoside-binding protein and participates in several biological processes, including modulation of immune response. In the literature, there are several reports about the potential therapeutic use of Gal-1 for autoimmune diseases, inflammatory, degenerative and infectious diseases. However, there are few reports on the involvement of Gal-1 in disease caused by Trypanosoma cruzi. Thus, this work was conducted to study the participation of endogenous and exogenous Gal-1 in acute experimental infection by T. cruzi. Recombinant Gal-1, galectin-1-deficient mice (KO - Gal-1-/-) or wild type (WT - Gal-1+/+) mice and macrophages from these animals were used to perform the in vivo and in vitro assays. The animals were infected with trypomastigotes of T. cruzi (strain Y), intraperitoneally. The biological parameters analyzed were parasitemia and survival; histopathology of heart tissue, measurement of nitric oxide by Griess reaction; leukocyte immunophenotyping by flow cytometry; cytokine detection by ELISA and the release rate of parasites in cultured macrophages. Infected-Gal-1-/- mice or infected-Gal-1+/+ mice treated with Gal-1 showed the lowest levels of parasitemia. Interestingly, all infected-KO mice survived after the infection, whereas the infected-WT mice showed a drastic reduction in survival. The absence of endogenous Gal-1 or the exogenous Gal-1 treatment promoted a drastic reduction on inflammatory cells infiltrate in the cardiac muscle of infected mice. The sera of infected-WT mice treated with Gal-1, but not untreated animals, showed high levels of IFN-. Additionally, sera from infected-KO mice showed lower levels of different cytokines (TNF-, IFN-, IL-4, IL-10 and IL-12) compared with serum samples from infected-WT animals. The number of spleen cells (T, B cells, macrophages, NK and NKT) were generally higher in WT mice than in KO mice after infection with T. cruzi. Interestingly, the peritoneal cavity of infected-KO mice presented an increased numbers of neutrophils and macrophages after 12h or 24h of infection, respectively. The peak of NO production induced by T. cruzi in Gal-1-/- macrophages was earlier and more intense than that obtained by Gal-1+/+ macrophage. Furthermore, Gal-1-/- macrophage released fewer parasites in vitro in comparison to Gal-1+/+ macrophages. Taken together, these results suggest that the absence of endogenous Gal-1 or treatment with exogenous Gal-1 promoted immunological profiles (innate and adaptative responses) that cooperate to the resolution of acute experimental infection by T. cruzi

Natural killer (NK) cells are a subpopulation of effector lymphocytes with cytotoxic activity and cytokine-producing functions considered as an integral part of the innate immune response. Functions of NK cells include tumour elimination, engagement and regulation of antiviral immune responses and regulation of immune cells by production and secretion of chemokines and cytokines. CD69 is a C-type lectin-like transmembrane receptor expressed in NK cells. CD69 is an activating receptor and acts also as a very early marker of lymphocyte activation. Putative protein ligands have been described for CD69 in the last years: Galectin-1, S1P1, S100A8/S100A9 and Myl9/12. Galectin-1 is a prototypical lectin characterized by the presence of a common lectin structural fold and a carbohydrate recognition domain involved in carbohydrate binding. Galectin-1 was identified as a binding partner for CD69 based on biological and functional studies, but structural details about the complex are still missing. This thesis describes the successful establishment of an expression protocol for a tag-less cysteine-less mutant of galectin-1 and the study of the interaction between galectin-1 and NK cell receptors. The interaction was studied using microscale thermophoresis and confirmed as dependent on the presence of a...

Modification by glycosylation gives proteins a range of diverse functions reflecting their structural variability. N-glycans regulate many biological outcomes in mammalian cells under both normal and pathological conditions. They play a major role in various pathologies such as cancer and lysosomal storage diseases. Interplay between N-glycans and other regulators, such as membrane lipid domains, in the control of signaling pathways remains poorly understood. My thesis therefore focuses on how N-glycans and membrane lipid domains oppose and/or work together at different cellular levels to regulate various processes such as receptor signaling and diffusion, endocytosis and lysosomal organelle biogenesis. Mgat5 encodes for ß1,6-N-acetylglucosaminyltransferase V that produces N-glycans, the preferred ligand for galectins. In tumor cells, galectins bind glycosylated receptors at the cell surface forming a lattice, that restricts receptor endocytosis and enhances its residency at the plasma membrane. In the first part of my thesis, I report that Galectin/receptor crosslinking opposes receptor sequestration by oligomerized caveolin-1 (Cav1) domains overriding its negative regulation of epidermal growth factor receptor (EGFR) signaling, cell surface diffusion and tumor growth. These results identify Cav1 as a conditional tumor suppressor. I also demonstrate that Cav1 is a negative regulator of lipid raft-mediated endocytosis. Cav1 indirectly regulates the internalization of cholera toxin b subunit to the Golgi apparatus independently of caveolae formation. That identifies a new role for caveolin-1 outside caveolae in the regulation of raft-dependent endocytosis Finally, Mgat5 overexpression in pneumocytes is associated with the expression of a lysosomal organelle, the multilamellar body (MLB), via autophagy. MLB expression is also a characteristic of various lysosomal storage diseases. I demonstrate that cholesterol accumulation can override the need for Mgat5 overexpression in MLB formation indicating that they may form via multiple mechanisms. However, I also demonstrate that a contribution of the autophagic pathway is a common determinant of biogenesis of MLB of various lipid compositions. In conclusion, Mgat5-dependent protein glycosylation and Cav1/raft domains therefore both function as regulators of plasma membrane interactions, endocytosis and lysosomal organelle biogenesis. Understanding of this interplay is crucial for the understanding of the mechanisms involve in various pathologies such as cancer and lysosomal storage diseases.

<p>The goal of this work is to develop novel molecular systems, functionalization techniques, and data collection routines with which to study the binding of immobilized cognate binding partners. Our ultimate goal is the routine evaluation of thermodynamic parameters for immobilized systems through interpretation of the variation of the binary probability of binding as a function of soluble ligand concentration. The development of both data collection routines that minimize non-specific binding and functionalization techniques that produce stable ordered molecular systems on surfaces are of paramount importance towards achievement of this goal. Methodologies developed here will be applied to investigating the thermodynamics of multivalent systems.</p><p>In the first part of this work, the effect of contact force on molecular recognition force microscopy experiments was investigated. Increased contact forces (>250 pN) resulted in increased probabilities of binding and decreased blocking efficiencies for the cognate ligand-receptor pair lactose-G3. Increased contact force applied to two control systems with no known affinity, mannose-G3 and lactose-KDPG aldolase resulted in non-specific ruptures that were indistinguishable from those of specific lactose-G3 interactions. Thus, it is essential to design data collections routines that minimize contact forces to ensure that ruptures originate from specific, blockable interactions.</p><p>In the second part of this work we report the first example of the preparation of stable self assembled monolayers through hydrosilylation of a protected aminoalkene onto hydrogen-terminated silicon nitride AFM probes and subsequent conjugation with biomolecules for force microscopy studies. Our technique can be used as a general attachment technique for other molecular systems.</p><p>In the third part of this work we develop novel molecular systems for tethering oriented vancomycin and its cognate binding partner L-Lys-D-Ala-D-Ala to surfaces and AFM tips. Unbinding experiments demonstrated that traditional methods for forming low surface density amine layers (silanization with APTMS and etherification with ethanolamine) provided molecular constructs which displayed probabilities of binding that were too low and showed overall variability too high to use for probabilistic evaluation of thermodynamics parameters. Instability and heat-induced polymerization of APTMS layers on tips and surfaces also prohibited their utility. Formation of Alkyl SAMs on silicon provides a more reliable, stable molecular system anchored by Si-C bonds that facilitates attachment of vancomycin and is capable of withstanding prolonged exposure to heated organic and aqueous environments. It follows that covalent immobilization of KDADA to silicon nitride AFM tips via Si-C bonds using hydrosilylation chemistry will be similarly advantageous. These methods offer great promise for probabilistic evaluation of thermodynamic parameters characterizing immobilized binding partners and will permit unambiguous determination of the role of multivalency in ligand binding, using an experimental configuration in which intermolecular binding and aggregation are precluded.</p> / Dissertation

Galectins are a family of secreted animal lectins with a high affinity to betagalactosides commonly involved in cellular functions such as apoptosis, adhesion and migration. Galectin 15 (LGALS15), a newest member of the galectin superfamily, has a unique C-terminal RGD sequence and participates in integrin-mediated ovine trophectoderm cell attachment and migration. In the ovine uterus, LGALS15 is expressed only by the endometrial luminal (LE) and superficial glandular (sGE) epithelia, induced by progesterone between Days 10 and 12 of the cycle and pregnancy, and then stimulated by interferon tau (IFNT) from the conceptus after Day 14 of pregnancy. During early pregnancy, the canonical janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is not active in the endometrial LE/sGE. Therefore, IFNT may utilizes a non-canonical signaling pathway to increase transcription of genes, including CST3, CTSL, HIF2A, LGALS15, and WNT7A, specifically in the endometrial LE/sGE. Alternatively, IFNT and progesterone could indirectly affect epithelial gene expression by influencing gene expression in the stroma, which then communicates with the epithelium. Although the LGALS15 gene is present in ovine, caprine and bovine species, it is only expressed in uteri of sheep and goats. Available data shows a tissue- and speciesspecific expression pattern for LGALS15, likely involving multiple layers of transcription regulation in the ruminant endometrium. Further analysis of the LGALS15 5? promoter/enhancer region revealed similar predicted transcription factor binding sites in all three species, including; PU.1, Ets-1, AP1, Sp1, and GRE or PRE sites. Interestingly, the proximal promoter region of the LGALS15 gene in all three species exhibited a conserved Sp1 binding site upstream of an AP1 binding site on both sense and antisense strands, and with similar spacing between binding sites. Sequence analysis revealed key differences in LGALS15 gene structure between ruminant species including the proximity of repetitive DNA sequences to the transcription start site (+1). Bovine LGALS15 has repetitive DNA sequences start at - 145 whereas in ovine or caprine LGALS15 it starts at about -300. The length of the repetitive DNA sequence is similar (~1.2 kb) in the 5' promoter/enhancer region of LGALS15 in all three species. Transient transfection analyses found that repetitive DNA sequences reduced basal promoter activity and responsiveness to treatments. None of the promoter construct showed responsiveness to interferon tau (IFNT). The bovine LGALS15 gene promoter showed no activity under any experimental conditions. The current studies indicate that uterine LGALS15 is expressed in ovine and caprine but not bovine species. Additionally, repetitive DNA sequences found in the promoter region may contribute to modulating the LGALS15 gene expression. Therefore, the ruminant LGALS15 gene, like other galectins, is under tight transcriptional control involving hormones, requisite transcription factors and potentially chromatin remodeling complexes working synergistically for LGALS15 promoter transactivation.